71.05
-0.42 (-0.59%)
Penutupan Terdahulu | 71.47 |
Buka | 71.47 |
Jumlah Dagangan | 127,581 |
Purata Dagangan (3B) | 1,794,205 |
Modal Pasaran | 2,391,545,088 |
Harga / Pendapatan (P/E TTM) | 66.40 |
Harga / Pendapatan (P/E Ke hadapan) | 54.35 |
Harga / Jualan (P/S) | 9.06 |
Harga / Buku (P/B) | 13.63 |
Julat 52 Minggu | |
Tarikh Pendapatan | 28 Apr 2025 - 2 May 2025 |
Margin Keuntungan | 10.03% |
Margin Operasi (TTM) | 19.12% |
EPS Cair (TTM) | 1.42 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 48.20% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | 110.60% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 194.67% |
Nisbah Semasa (MRQ) | 9.10 |
Aliran Tunai Operasi (OCF TTM) | 49.38 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -84.81 M |
Pulangan Atas Aset (ROA TTM) | 4.21% |
Pulangan Atas Ekuiti (ROE TTM) | 22.99% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Devices (US) | Menurun | Menurun |
Medical Devices (Global) | Menurun | Menurun | |
Stok | TransMedics Group, Inc. | Menurun | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 1.0 |
Aktiviti Orang Dalam | 4.0 |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 4.0 |
Purata | 2.20 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
Sektor | Healthcare |
Industri | Medical Devices |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 3.03% |
% Dimiliki oleh Institusi | 121.56% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 150.00 (Oppenheimer, 111.13%) | Beli |
Median | 143.50 (101.99%) | |
Rendah | 123.00 (Morgan Stanley, 73.13%) | Pegang |
Purata | 140.00 (97.06%) | |
Jumlah | 3 Beli, 1 Pegang | |
Harga Purata @ Panggilan | 125.56 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Morgan Stanley | 01 Aug 2025 | 123.00 (73.13%) | Pegang | 120.55 |
Canaccord Genuity | 15 Jul 2025 | 142.00 (99.87%) | Beli | 115.68 |
Oppenheimer | 17 Jun 2025 | 150.00 (111.13%) | Beli | 136.20 |
Piper Sandler | 04 Jun 2025 | 145.00 (104.10%) | Beli | 129.81 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
04 Aug 2025 | Pengumuman | TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial |
01 Aug 2025 | Pengumuman | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
30 Jul 2025 | Pengumuman | TransMedics Reports Second Quarter 2025 Financial Results |
29 Jul 2025 | Pengumuman | TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference |
16 Jul 2025 | Pengumuman | TransMedics to Report Second Quarter 2025 Financial Results on July 30, 2025 |
27 May 2025 | Pengumuman | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |